|
|
OSUCCC
 |
Gregory A. Otterson, M.D.
Assoc Professor
College of Medicine
Internal Medicine - Hematology/Oncology
B415 Starling Loving
320 W. 10th Avenue Columbus,OH. 43210
o |
(614) 293-2887 |
f |
(614) 293-4372 |
|
Programs
|
 |
|
|
Current Publications
|
|
Lung Cancer in press: , 2009
|
|
A psychometric analysis of quality of life tools in lung cancer patients who smoke.
|
|
Browning KK, Ferketich AK, Otterson GA, Reynolds NR, Wewers ME
|
|
|
Cancer Chemother Pharmacol in press: , 2009
|
|
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
|
|
Ntukidem N, Arce-Lara C, Otterson GA, Kraut E, Cataland S, Bekaii-Saab T
|
|
|
PLoS One 4(5): e5563, 2009
|
|
Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice.
|
|
Duan W, Gao L, Wu X, Hade EM, Gao JX, Ding H, Barsky SH, Otterson GA, Villalona-Calero MA
|
|
|
Biochem Biophys Res Commun 388(3): 483-9, 2009
|
|
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.
|
|
Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA, Nana-Sinkam SP
|
|
|
J Thorac Oncol 4(8): 1028-34, 2009
|
|
MicroRNAs in the pathogenesis of Lung Cancer.
|
|
Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, Otterson GA, Nana-Sinkam SP
|
|
|
J Clin Oncol 27(31): 5270-7, 2009
|
|
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
|
|
Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE 3rd
|
|
|
Cancer 115(19): 4434-41, 2009
|
|
Pulmonary neuroendocrine/carcinoid tumors: a review article.
|
|
Bertino EM, Confer PD, Colonna JE, Ross P, Otterson GA
|
|
|
Cancer Nurs 32(4): E15-25, 2009
|
|
The Self-regulation Model of Illness applied to smoking behavior in lung cancer.
|
|
Browning KK, Wewers ME, Ferketich AK, Otterson GA, Reynolds NR
|
|
|
PLoS One 3(6): e2445, 2008
|
|
HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells.
|
|
Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, Lu S, Yu Y, Wang H, McNutt MA, Hu YG, Chen Y, Yang Y, Wu X, Otterson GA, Zhu WG
|
|
|
Transgenic Res 17(3): 355-66, 2008
|
|
Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice.
|
|
Duan W, Gao L, Jin D, Otterson GA, Villalona MA
|
|
|
Biochem Biophys Res Commun 373(4): 607-12, 2008
|
|
MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines.
|
|
Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, Nuovo G, Marsh CB, Nana-Sinkam SP
|
|
|
Ann Oncol 19(11): 1903-9, 2008
|
|
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
|
|
Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL, Villalona-Calero MA
|
|
|
J Natl Compr Canc Netw 6(3): 228-69, 2008
|
|
Non-small cell lung cancer.
|
|
Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE
|
|
|
Cancer Chemother Pharmacol 63(6): 1073-82, 2008
|
|
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
|
|
Kolesar JM, Schaaf LJ, Drengler R, Duan W, Otterson G, Shapiro C, Kuhn J, Villalona-Calero MA
|
|
|
Trends Genet 23(9): 449-56, 2008
|
|
Unraveling the epigenetic code of cancer for therapy.
|
|
Smith LT, Otterson GA, Plass C
|
|
|
